Tags

Type your tag names separated by a space and hit enter

Prognostic value of natriuretic peptides in Chagas' disease: a 3-year follow-up investigation.
Cardiology. 2008; 110(4):217-25.C

Abstract

BACKGROUND

Chagas' disease (CD) affects around 18 million people in Latin America. To determine the diagnostic and prognostic value of natriuretic peptides in patients with CD, we measured atrial (ANP) and brain natriuretic peptide (BNP), and compared the findings with other dilated cardiomyopathies (DCM).

METHODS

Blood samples were obtained from 111 CD patients, 62 patients with DCM due to other causes, and 43 gender- and age-matched healthy subjects. The CD and DCM patients were subdivided according to their NYHA classification. Natriuretic peptide concentrations were determined by immunoradiometric assays.

RESULTS

ANP and more pronounced BNP levels were increased in CD and DCM patients in relation to the NYHA class. Circulating BNP concentrations were higher in CD patients in NYHA classes I-II than in the corresponding DCM patients (p = 0.020). Importantly, ANP and BNP were already significantly elevated in CD patients without systolic ventricular dysfunction (p < or = 0.001). In CD patients, both peptides were highly correlated with echocardiographic parameters (p < 10(-14)). Both ANP and BNP had comparable ability to predict death or the necessity for heart transplant (p < 0.0001).

CONCLUSION

Natriuretic peptide levels can be used as a marker of asymptomatic CD without ventricular dysfunction and thus could be an ideal tool to identify these patients for early therapy.

Authors+Show Affiliations

Department of Internal Medicine, Felicio Rocho Hospital, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18073475

Citation

Moreira, Maria da Consolação V., et al. "Prognostic Value of Natriuretic Peptides in Chagas' Disease: a 3-year Follow-up Investigation." Cardiology, vol. 110, no. 4, 2008, pp. 217-25.
Moreira Mda C, Heringer-Walther S, Wessel N, et al. Prognostic value of natriuretic peptides in Chagas' disease: a 3-year follow-up investigation. Cardiology. 2008;110(4):217-25.
Moreira, M. d. a. . C., Heringer-Walther, S., Wessel, N., Moreira Ventura, T., Wang, Y., Schultheiss, H. P., & Walther, T. (2008). Prognostic value of natriuretic peptides in Chagas' disease: a 3-year follow-up investigation. Cardiology, 110(4), 217-25.
Moreira Mda C, et al. Prognostic Value of Natriuretic Peptides in Chagas' Disease: a 3-year Follow-up Investigation. Cardiology. 2008;110(4):217-25. PubMed PMID: 18073475.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prognostic value of natriuretic peptides in Chagas' disease: a 3-year follow-up investigation. AU - Moreira,Maria da Consolação V, AU - Heringer-Walther,Silvia, AU - Wessel,Niels, AU - Moreira Ventura,Tiago, AU - Wang,Yong, AU - Schultheiss,Heinz-Peter, AU - Walther,Thomas, Y1 - 2007/12/12/ PY - 2007/03/21/received PY - 2007/06/05/accepted PY - 2007/12/13/pubmed PY - 2008/7/11/medline PY - 2007/12/13/entrez SP - 217 EP - 25 JF - Cardiology JO - Cardiology VL - 110 IS - 4 N2 - BACKGROUND: Chagas' disease (CD) affects around 18 million people in Latin America. To determine the diagnostic and prognostic value of natriuretic peptides in patients with CD, we measured atrial (ANP) and brain natriuretic peptide (BNP), and compared the findings with other dilated cardiomyopathies (DCM). METHODS: Blood samples were obtained from 111 CD patients, 62 patients with DCM due to other causes, and 43 gender- and age-matched healthy subjects. The CD and DCM patients were subdivided according to their NYHA classification. Natriuretic peptide concentrations were determined by immunoradiometric assays. RESULTS: ANP and more pronounced BNP levels were increased in CD and DCM patients in relation to the NYHA class. Circulating BNP concentrations were higher in CD patients in NYHA classes I-II than in the corresponding DCM patients (p = 0.020). Importantly, ANP and BNP were already significantly elevated in CD patients without systolic ventricular dysfunction (p < or = 0.001). In CD patients, both peptides were highly correlated with echocardiographic parameters (p < 10(-14)). Both ANP and BNP had comparable ability to predict death or the necessity for heart transplant (p < 0.0001). CONCLUSION: Natriuretic peptide levels can be used as a marker of asymptomatic CD without ventricular dysfunction and thus could be an ideal tool to identify these patients for early therapy. SN - 1421-9751 UR - https://www.unboundmedicine.com/medline/citation/18073475/Prognostic_value_of_natriuretic_peptides_in_Chagas'_disease:_a_3_year_follow_up_investigation_ L2 - https://www.karger.com?DOI=10.1159/000112403 DB - PRIME DP - Unbound Medicine ER -